Lurasidone

Schizophrenia

Lurasidone is used to treat the symptoms of schizophrenia in adults and adolescents aged 13 to 17 years. It helps manage symptoms such as hallucinations, delusions, and disorganized thinking.

Bipolar Depression

This medication is also used to treat major depressive episodes associated with bipolar I disorder, sometimes called manic depression. It is used in two primary ways for this condition:

• Monotherapy: It can be used alone to treat bipolar depression in adults and children who are at least 10 years old.
• Adjunctive therapy: It can be used in combination with other medications, such as lithium or valproate, to treat bipolar depression in adults.

Lurasidone belongs to a class of drugs known as atypical antipsychotics. It works by changing the activity of certain natural substances in the brain.

Mechanism of Action

Lurasidone belongs to a class of medications known as atypical antipsychotics. While the exact way it works is not completely understood, it is believed to help restore the balance of certain natural substances in the brain called neurotransmitters.

The medication primarily affects the following chemicals in the brain:

• Dopamine: Lurasidone blocks certain dopamine receptors. This action is thought to help reduce symptoms such as hallucinations, delusions, and disorganized thinking.
• Serotonin: The drug also interacts with several types of serotonin receptors. By acting on these receptors, it helps regulate mood and may improve symptoms of depression.

By influencing these chemical pathways, lurasidone helps stabilize brain activity, which can improve concentration, mood, and the ability to think clearly.

Common Side Effects

The most frequently reported side effects of lurasidone include:

• Drowsiness or sleepiness
• Restlessness or a constant need to move (akathisia)
• Nausea and vomiting
• Muscle stiffness or tremors
• Stomach pain or indigestion
• Weight gain

Serious Side Effects

Seek medical attention immediately if you experience any of the following serious side effects:

• Uncontrolled movements: Twitching or repetitive movements of the face, tongue, or limbs (tardive dyskinesia).
• Severe nervous system reaction: High fever, stiff muscles, confusion, sweating, or fast heartbeats (neuroleptic malignant syndrome).
• High blood sugar: Increased thirst, frequent urination, fruity breath odor, or blurred vision.
• Low white blood cell count: Fever, chills, sore throat, or other signs of infection.
• Dizziness or fainting: A sudden drop in blood pressure when standing up.
• Difficulty swallowing: Problems moving food or liquid through the throat.
• Seizures: Sudden changes in behavior or consciousness.
• Temperature regulation issues: Becoming overheated easily or having difficulty cooling down.

Boxed Warnings

Increased Mortality in Elderly Patients with Dementia-Related Psychosis: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Lurasidone is not approved for the treatment of patients with dementia-related psychosis.

Suicidal Thoughts and Behaviors: Antidepressants may increase the risk of suicidal thoughts and behaviors in children, adolescents, and young adults. Patients of all ages starting therapy should be monitored closely for worsening symptoms or unusual changes in behavior.

Contraindications

Lurasidone should not be used by individuals with a known hypersensitivity to the drug. It is also contraindicated for use with strong CYP3A4 inhibitors (such as ketoconazole or clarithromycin) and strong CYP3A4 inducers (such as rifampin or St. John's wort), as these can significantly alter drug levels in the body.

Serious Adverse Reactions

Neuroleptic Malignant Syndrome (NMS)

NMS is a rare but potentially fatal condition associated with antipsychotic medication. Symptoms may include high fever, muscle rigidity, delirium, and autonomic instability, such as irregular pulse or blood pressure.

Tardive Dyskinesia

This condition involves involuntary, repetitive body movements, often in the face or tongue. The risk increases with the duration of treatment and the total cumulative dose, and it may become irreversible.

Metabolic Changes

Atypical antipsychotics are associated with metabolic risks, including:

• Hyperglycemia and Diabetes Mellitus: Blood glucose levels may rise significantly; regular monitoring is recommended.
• Dyslipidemia: Changes in cholesterol and triglyceride levels may occur.
• Weight Gain: Significant weight gain has been observed in clinical trials.

Other Precautions

• Blood Disorders: Cases of leukopenia, neutropenia, and agranulocytosis (dangerously low white blood cell counts) have been reported. Periodic blood count monitoring may be necessary.
• Orthostatic Hypotension: Some patients may experience a drop in blood pressure when standing up, leading to dizziness or fainting.
• Seizures: Lurasidone should be used with caution in patients with a history of seizures or conditions that lower the seizure threshold.
• Cognitive and Motor Impairment: The medication may cause somnolence (drowsiness), which can impair the ability to drive or operate machinery.
• Body Temperature Regulation: Antipsychotics can disrupt the body's ability to reduce core temperature, increasing the risk of overheating during strenuous exercise or exposure to extreme heat.

Pregnancy

There is limited data on the use of lurasidone in pregnant individuals. Taking antipsychotic medications like lurasidone during the third trimester of pregnancy may cause the newborn to experience extrapyramidal symptoms or withdrawal symptoms after delivery. These symptoms can include:

• Agitation or tremors
• Increased or decreased muscle tone
• Drowsiness
• Difficulty breathing
• Feeding problems

The severity of these symptoms varies; some infants may recover quickly, while others may require medical intervention or hospitalization. A pregnancy exposure registry exists to monitor the health of individuals and their infants when antipsychotic medications are used during pregnancy.

Breastfeeding

It is not known whether lurasidone passes into human breast milk. Animal studies have shown that the drug is present in the milk of lactating animals. Because of the potential for serious adverse reactions in a nursing infant, a decision should be made with a healthcare provider whether to stop breastfeeding or stop the medication, taking into account the importance of the drug to the mother's health.

Dosage Forms

Lurasidone is supplied in the following form:

• Oral Tablet: A solid medication taken by mouth.

This medication is available in various strengths to allow for dosing adjustments. It is important to take the specific strength prescribed by a healthcare provider, as different strengths may be used depending on the individual's needs and the condition being treated.

FDA Approval and Indications

Lurasidone was first approved by the U.S. Food and Drug Administration (FDA) in 2010. It is currently approved for the following indications:

• Schizophrenia: Treatment in adults and adolescents aged 13 to 17 years.
• Bipolar Depression: Treatment of major depressive episodes associated with Bipolar I Disorder. It may be used as monotherapy in adults and pediatric patients aged 10 to 17 years, or as adjunctive therapy with lithium or valproate in adults.

Boxed Warnings

The FDA requires a boxed warning for lurasidone to highlight two major safety concerns:

• Increased Mortality in Elderly Patients with Dementia-Related Psychosis: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Lurasidone is not approved for the treatment of patients with dementia-related psychosis.
• Suicidal Thoughts and Behaviors: While lurasidone is an antipsychotic, it is used to treat depressive episodes. Antidepressants have been shown to increase the risk of suicidal thoughts and behaviors in children, adolescents, and young adults. Patients should be monitored closely for clinical worsening or emergence of suicidal thoughts.

Regulatory Classification

Lurasidone is a prescription-only medication. It is not a controlled substance under the Controlled Substances Act. Generic versions of the medication have been approved by the FDA, increasing its availability as a lower-cost alternative to brand-name versions.

Weight Gain and Monitoring

Weight gain is a potential side effect of lurasidone. While it is often associated with a lower risk of weight gain compared to some other antipsychotic medications, clinical studies have shown that some patients still experience increases in body weight.

In clinical trials involving adults, a small percentage of patients experienced a weight gain of 7% or more. Pediatric patients, including children and adolescents, may also experience weight changes. Because of these risks, healthcare providers will typically monitor weight and other metabolic factors throughout treatment.

Monitoring usually includes:

• Regular weight and body mass index (BMI) checks
• Blood sugar testing to monitor for hyperglycemia
• Blood tests for cholesterol and triglyceride levels

Patients are encouraged to report any significant or rapid weight changes to their healthcare provider. Management may involve lifestyle modifications or adjustments to the treatment plan.